urology

Studies reveal drop in PCa treatment, rise in metastatic diseaseFindings from two new studies provide insight on the impact of changing recommendations for prostate cancer screening and management.
Bone metastases Tx: 12-week dosing interval appears feasibleResults of a 2-year clinical trial support switching to a less frequent administration schedule when using zoledronic acid (Zometa) to prevent skeletal-related events in men with prostate cancer.
Uro Pipeline: FDA accepts biologics license application for bladder Ca agentOther pipeline developments discussed include an implantable device for OAB treatment, a subcutaneous hypogonadism treatment, efficacy results for an HPV drug, and the status of a device-based BPH treatment.
Letters: Hypoactive desire disorder a 'true' conditionIn this month's Letters to the Editor, one reader responds to an article on testosterone therapy in women and another looks to address urology's work force shortage.
Does increased stress lead to heart attack?In this edition of Men’s Health Mythbuster, Matthew Pollard, MD, Jesse N. Mills, MD look at what impact stress really has on the cardiovascular system.
HHS nominee Dr. Price promises physician-friendly reformsTom Price, MD, would play a key role in repealing the Affordable Care Act and making significant changes to Medicare if confirmed as Secretary of Health and Human Services.
Medical expulsive therapy or bust?Whether or not medical expulsive therapy (MET) is a sound recommendation for patients with kidney or ureteral stones is a matter of debate.
Men's health: What you may have missed in 2016Our #LetsTalkMensHealth section offers clinical tips on the care of male patients. In 2016, articles in this section tackled a variety of subjects, including the Affordable Care Act, epigenetics and genetics, and BPH and prostate cancer prevention.
Pain control: Let’s rethink our prescribing habitsDr. Henry Rosevear apologizes to those he may have hurt with his prescription habits for pain control and discusses the steps he is taking to help remedy the narcotics epidemic.
PCa immunotherapy: Response better when given before ADTAdministering sipuleucel-T (Provenge) before rather than after androgen deprivation therapy in men with biochemically recurrent prostate cancer appears to result in a more robust immunologic response, according to a recent study.